Stanford scientists have developed a novel hydrogel for long-term drug delivery of an Activator Protein 1 (AP-1) inhibitor for the prevention of post-surgical abdominal adhesion.
Stanford inventors have discovered that applying a hydrogel containing an inhibitor of mechanotransduction pathways on top of a skin graft reduces scarring and promotes healing after repair of traumatic injuries like severe burn wounds.